Saniona AB (STU:30S) EPS (Basic): €0.14 (TTM As of Mar. 2026)


STU:30S Saniona AB STU:30S
61 GF Score
Price €1.13
GF Value €2.44
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Saniona AB EPS (Basic)?

Saniona AB STU:30S +1.34% 61 EPS (Basic) is €0.14 as of Mar. 2026. GuruFocus rates STU:30S with a GF Score™ of 61/100 and a GF Value™ of €2.44 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Saniona AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.14.

Saniona AB's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.14.

Saniona AB's EPS without NRI for the three months ended in Mar. 2026 was €-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.14.

During the past 12 months, Saniona AB's average EPS without NRIGrowth Rate was -18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Saniona AB's highest 3-Year average EPS without NRI Growth Rate was 26.80% per year. The lowest was -121.30% per year. And the median was -16.85% per year.

Saniona AB  (STU:30S) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Saniona AB EPS (Basic) Related Terms

Saniona AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Saniona AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Saniona AB EPS (Basic) Chart

Saniona AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.54 -0.26 -0.12 0.15 0.20

Saniona AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.02 0.22 -0.03 -0.03
STU:30S
61GF Score
Saniona AB STU:30S
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Saniona AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Saniona AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(26.159-0)/128.884
=0.20

Saniona AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4.285-0)/138.030
=-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €0.14 mean?
Saniona AB (STU:30S) has a EPS (Basic) of €0.14 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Saniona AB and its competitors.
Is Saniona AB's EPS (Basic) too high?
Saniona AB's current EPS (Basic) is €0.14. Overall, Saniona AB has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's EPS (Basic) compare to VRTX and REGN?
Saniona AB's EPS (Basic) of €0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Saniona AB and its competitors. Saniona AB's current EPS (Basic) is €0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (STU:30S) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.44, compared to a current price of €1.13 — trading 53.6% below its estimated fair value. The current EPS (Basic) is €0.14. Saniona AB's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Saniona AB (STU:30S), the current EPS (Basic) is €0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Saniona AB (STU:30S) Overvalued in 2026?

Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued. The current stock price of €1.13 is trading 53.6% below its estimated GF Value™ of €2.44. GuruFocus considers Saniona AB to be Significantly Undervalued.

Key valuation signals for STU:30S:

  • EPS (Basic): €0.14
  • GF Value™: €2.44 vs. price of €1.13 (53.6% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the STU:30S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Saniona AB Business Description

Address Murervangen 42, Glostrup, DNK, DK-2600
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
61GF Score

Get the complete analysis for STU:30S

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.13
Price
€2.44
GF Value